Our top pick for
Building a portfolio
Larimar Therapeutics, Inc is a biotechnology business based in the US. Larimar Therapeutics shares (LRMR) are listed on the NASDAQ and all prices are listed in US Dollars. Larimar Therapeutics employs 28 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$8.64 - $25.87|
|50-day moving average||$16.41|
|200-day moving average||$18.73|
|Wall St. target price||$35.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-11.53|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-48.69%|
|Return on equity TTM||-95.47%|
|Market capitalisation||$190.4 million|
TTM: trailing 12 months
There are currently 307,755 Larimar Therapeutics shares held short by investors – that's known as Larimar Therapeutics's "short interest". This figure is 12% up from 274,668 last month.
There are a few different ways that this level of interest in shorting Larimar Therapeutics shares can be evaluated.
Larimar Therapeutics's "short interest ratio" (SIR) is the quantity of Larimar Therapeutics shares currently shorted divided by the average quantity of Larimar Therapeutics shares traded daily (recently around 54858.288770053). Larimar Therapeutics's SIR currently stands at 5.61. In other words for every 100,000 Larimar Therapeutics shares traded daily on the market, roughly 5610 shares are currently held short.
However Larimar Therapeutics's short interest can also be evaluated against the total number of Larimar Therapeutics shares, or, against the total number of tradable Larimar Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Larimar Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Larimar Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0321% of the tradable shares (for every 100,000 tradable Larimar Therapeutics shares, roughly 32 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Larimar Therapeutics.
Find out more about how you can short Larimar Therapeutics stock.
We're not expecting Larimar Therapeutics to pay a dividend over the next 12 months.
Larimar Therapeutics's shares were split on a 1:12 basis on 28 May 2020. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Larimar Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Larimar Therapeutics shares which in turn could have impacted Larimar Therapeutics's share price.
Larimar Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania. .
Everything we know about the Talaris Therapeutics IPO, plus information on how to buy in.
Everything we know about the Sagimet Biosciences IPO, plus information on how to buy in.
Everything we know about the Zenvia IPO, plus information on how to buy in.
Everything we know about the Grove IPO, plus information on how to buy in.
Everything we know about the Pasithea Therapeutics IPO, plus information on how to buy in.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.